QID 216264

Date Published: 2021-09-20

QID 216264: VMware ESXi 6.5 Patch Release ESXi650-202107401-SG Missing (VMSA-2021-0014)

VMware ESXi is an enterprise level computer virtualization product.

SFCB (Small Footprint CIM Broker) as used in ESXi has an authentication bypass vulnerability.

Affected Versions:
VMware ESXi 6.5 prior to build 18071574

QID Detection Logic (Unauthenticated):
This QID checks for vulnerable versions of VMware ESXi with build version using web service present on the target.

QID Detection Logic (Authenticated):
This QID checks whether the SFCB service (CIM Server) service and SLP service are off as mentioned in the workaround. If both services are off, QID will not flag.

A malicious actor with network access to port 5989 on ESXi may exploit this issue to bypass SFCB authentication by sending a specially crafted request.

CVSS V3 rated as Critical - 9.8 severity.

CVSS V2 rated as High - 6.8 severity.

Solution

VMware has released patch for VMware ESXi 6.5 , visit VMware ESXi 6.5 , Patch Release ESXi650-202107401-SG
Refer to VMware advisory VMSA-2021-0014 for more information.

Workaround:
For CVE-2021-21994
Disable the SFCB service (CIM Server) on the ESX/ESXi host
Please visit here for more information.

For CVE-2021-21995
Disable the SLP service on the ESX/ESXi host
Please visit here for more information.

Vendor References

VMSA-2021-0014 - www.vmware.com/security/advisories/VMSA-2021-0014.html

CVEs related to QID 216264

CVE-2021-21994 | CVE-2021-21995 |

Software Advisories

Advisory ID	Software	Component	Link
VMware ESXi 6.5 ESXi650-202107401-SG			docs.vmware.com/en/VMware-vSphere/6.5/rn/esxi650-202107001.html

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].